Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Farren

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Biochimica Et Biophysica Acta|November 12, 2013
Autocrine GM-CSF transcription in the leukemic progenitor cell line KG1a is mediated by the transcription factor ETS1 and is negatively regulated through SECTM1 mediated ligation of CD7Christina Bade-Döding, Wiebke Göttmann, Anja Baigger, et al.
Cancer|May 9, 2020
Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancerGanji Purnachandra Nagaraju, Batoul Farran, Matthew Farren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2013
Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapyNeil R Smith, Dawn Baker, Matthew Farren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2014
Tumor stromal phenotypes define VEGF sensitivity--responseNeil R Smith, Dawn Baker, Matthew Farren, et al.
Angiogenesis|May 31, 2012
Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologiesMatthew Farren, Susie Weston, Helen Brown, et al.
Plos One|July 11, 2013
RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor CediranibJames R Bradford, Matthew Farren, Steve J Powell, et al.
Cell Metabolism|December 3, 2015
Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal CancerAurélien J C Pommier, Matthew Farren, Bhavika Patel, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Biochimica Et Biophysica Acta|November 12, 2013
Autocrine GM-CSF transcription in the leukemic progenitor cell line KG1a is mediated by the transcription factor ETS1 and is negatively regulated through SECTM1 mediated ligation of CD7Christina Bade-Döding, Wiebke Göttmann, Anja Baigger, et al.
Cancer|May 9, 2020
Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancerGanji Purnachandra Nagaraju, Batoul Farran, Matthew Farren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2013
Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapyNeil R Smith, Dawn Baker, Matthew Farren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2014
Tumor stromal phenotypes define VEGF sensitivity--responseNeil R Smith, Dawn Baker, Matthew Farren, et al.
Angiogenesis|May 31, 2012
Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologiesMatthew Farren, Susie Weston, Helen Brown, et al.
Plos One|July 11, 2013
RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor CediranibJames R Bradford, Matthew Farren, Steve J Powell, et al.
Cell Metabolism|December 3, 2015
Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal CancerAurélien J C Pommier, Matthew Farren, Bhavika Patel, et al.
Pageof 1